The European Journal of Cancer Prevention publishes an article by Olga Sjomina, a research assistant at the Institute of Clinical and Preventive Medicine at the University of Latvia

Our new article, "Randomized Clinical Trial: Efficacy and Safety of H. pylori Eradication Treatment with or without Saccharomyces boulardii supplementation," was published in the European Journal of Cancer Prevention. The journal aims to promote increased awareness of all aspects of cancer prevention and stimulate new ideas and innovations.
In the study, Dr. Olga Sjomina and colleagues analyzed how the probiotic Saccharomyces boulardii influenced the efficacy and safety of the standard triple eradication scheme for Helicobacter pylori, as well as the spectrum of side effects. It was found that the probiotic overall improved patient compliance, reduced the frequency of antibiotic-induced diarrhea during the 14-day eradication period, and showed a tendency to enhance the efficacy of eradication in the intention-to-treat group receiving a 10-day therapy. The results of the study will help improve the possibilities of H. pylori eradication to reduce the risk of gastric cancer development.
The study was conducted as part of the GISTAR project in collaboration with international colleagues Dr. Jin Young Park and  Dr. Viktoria Knaze from the International Agency for Research on Cancer (IARC), Dr. Raul Murillo (General Director of the National Cancer Institute of Colombia), and Dr. Rolando Herrero (Medical Oncology Specialist, Medical Oncology, University of Costa Rica). The project was implemented with the support of the European Regional Development Fund (ERDF) within the framework of the 2nd part of measure 1.1.1.1. "Practical Studies," project ID No. 1.1.1.1/18/A/184, "Optimization of H. pylori Eradication Therapy for Population-Based Gastric Cancer Prevention."